<?xml version='1.0' encoding='utf-8'?>
<document id="19663817"><sentence text="Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes."><entity charOffset="60-71" id="DDI-PubMed.19663817.s1.e0" text="fluvastatin" /></sentence><sentence text="Fluvastatin has been considered to be metabolised to 5-hydroxy fluvastatin (M-2), 6-hydroxy fluvastatin (M-3) and N-desisopropyl fluvastatin (M-5) in human liver microsomes by primarily CYP2C9"><entity charOffset="0-11" id="DDI-PubMed.19663817.s2.e0" text="Fluvastatin" /><entity charOffset="53-74" id="DDI-PubMed.19663817.s2.e1" text="5-hydroxy fluvastatin" /><entity charOffset="82-103" id="DDI-PubMed.19663817.s2.e2" text="6-hydroxy fluvastatin" /><entity charOffset="114-140" id="DDI-PubMed.19663817.s2.e3" text="N-desisopropyl fluvastatin" /><pair ddi="false" e1="DDI-PubMed.19663817.s2.e0" e2="DDI-PubMed.19663817.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19663817.s2.e0" e2="DDI-PubMed.19663817.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19663817.s2.e0" e2="DDI-PubMed.19663817.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19663817.s2.e0" e2="DDI-PubMed.19663817.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19663817.s2.e1" e2="DDI-PubMed.19663817.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19663817.s2.e1" e2="DDI-PubMed.19663817.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19663817.s2.e1" e2="DDI-PubMed.19663817.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19663817.s2.e2" e2="DDI-PubMed.19663817.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19663817.s2.e2" e2="DDI-PubMed.19663817.s2.e3" /></sentence><sentence text=" To elucidate the contribution of different CYP enzymes on fluvastatin metabolism, we examined the effect of CYP inhibitors and CYP2C-specific monoclonal antibodies on the formation of fluvastatin metabolites in human liver microsomes"><entity charOffset="59-70" id="DDI-PubMed.19663817.s3.e0" text="fluvastatin" /><entity charOffset="185-196" id="DDI-PubMed.19663817.s3.e1" text="fluvastatin" /><pair ddi="false" e1="DDI-PubMed.19663817.s3.e0" e2="DDI-PubMed.19663817.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19663817.s3.e0" e2="DDI-PubMed.19663817.s3.e1" /></sentence><sentence text=" Human liver microsomes were incubated with fluvastatin with or without pre-treatment with CYP inhibitors or monoclonal antibodies"><entity charOffset="44-55" id="DDI-PubMed.19663817.s4.e0" text="fluvastatin" /></sentence><sentence text=" Selective inhibitors of CYP2C9 (sulfaphenazole), CYP3A (ketoconazole) and CYP2C8 (quercetin) were employed and monoclonal antibodies were against CYP2C8, CYP2C9, CYP2C19 and CYP2C8/9/18/19"><entity charOffset="25-31" id="DDI-PubMed.19663817.s5.e0" text="CYP2C9" /><entity charOffset="33-47" id="DDI-PubMed.19663817.s5.e1" text="sulfaphenazole" /><entity charOffset="50-55" id="DDI-PubMed.19663817.s5.e2" text="CYP3A" /><entity charOffset="57-69" id="DDI-PubMed.19663817.s5.e3" text="ketoconazole" /><entity charOffset="75-81" id="DDI-PubMed.19663817.s5.e4" text="CYP2C8" /><entity charOffset="83-92" id="DDI-PubMed.19663817.s5.e5" text="quercetin" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e0" e2="DDI-PubMed.19663817.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e0" e2="DDI-PubMed.19663817.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e0" e2="DDI-PubMed.19663817.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e0" e2="DDI-PubMed.19663817.s5.e3" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e0" e2="DDI-PubMed.19663817.s5.e4" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e0" e2="DDI-PubMed.19663817.s5.e5" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e1" e2="DDI-PubMed.19663817.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e1" e2="DDI-PubMed.19663817.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e1" e2="DDI-PubMed.19663817.s5.e3" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e1" e2="DDI-PubMed.19663817.s5.e4" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e1" e2="DDI-PubMed.19663817.s5.e5" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e2" e2="DDI-PubMed.19663817.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e2" e2="DDI-PubMed.19663817.s5.e3" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e2" e2="DDI-PubMed.19663817.s5.e4" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e2" e2="DDI-PubMed.19663817.s5.e5" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e3" e2="DDI-PubMed.19663817.s5.e3" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e3" e2="DDI-PubMed.19663817.s5.e4" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e3" e2="DDI-PubMed.19663817.s5.e5" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e4" e2="DDI-PubMed.19663817.s5.e4" /><pair ddi="false" e1="DDI-PubMed.19663817.s5.e4" e2="DDI-PubMed.19663817.s5.e5" /></sentence><sentence text=" According to the amount of fluvastatin metabolites produced, the formation of M-3 was found to be major pathway of fluvastatin metabolism (the relative contribution was calculated to be more than 80%)"><entity charOffset="28-39" id="DDI-PubMed.19663817.s6.e0" text="fluvastatin" /><entity charOffset="116-127" id="DDI-PubMed.19663817.s6.e1" text="fluvastatin" /><pair ddi="false" e1="DDI-PubMed.19663817.s6.e0" e2="DDI-PubMed.19663817.s6.e0" /><pair ddi="false" e1="DDI-PubMed.19663817.s6.e0" e2="DDI-PubMed.19663817.s6.e1" /></sentence><sentence text=" Sulfaphenazole inhibited the formation of M-2 largely, but had little effect on the formation of M-3"><entity charOffset="1-15" id="DDI-PubMed.19663817.s7.e0" text="Sulfaphenazole" /></sentence><sentence text=" It also inhibited the formation of M-5" /><sentence text=" Ketoconazole markedly inhibited the formation of M-3, but did not inhibit the formation of M-2 and M-5"><entity charOffset="1-13" id="DDI-PubMed.19663817.s9.e0" text="Ketoconazole" /></sentence><sentence text=" Quercetin had a moderate inhibitory effect on the formation of all three fluvastatin metabolites"><entity charOffset="1-10" id="DDI-PubMed.19663817.s10.e0" text="Quercetin" /><entity charOffset="74-85" id="DDI-PubMed.19663817.s10.e1" text="fluvastatin" /><pair ddi="false" e1="DDI-PubMed.19663817.s10.e0" e2="DDI-PubMed.19663817.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19663817.s10.e0" e2="DDI-PubMed.19663817.s10.e1" /></sentence><sentence text=" Monoclonal antibodies against CYP2C9 and CYP2C8/9/18/19 markedly inhibited the formation of M-2 and M-5" /><sentence text=" None of monoclonal antibodies showed clear inhibition on the formation of M-3" /><sentence text=" In contrast to previous published work, our results suggest that M-2 and M-5 are formed preferentially by CYP2C9, and that M-3 is mainly formed by CYP3A"><entity charOffset="148-158" id="DDI-PubMed.19663817.s13.e0" text="CYP3A" /></sentence><sentence text=" In summary, the results contribute to a better understanding of the drug-drug interaction potential for fluvastatin in vivo"><entity charOffset="105-116" id="DDI-PubMed.19663817.s14.e0" text="fluvastatin" /></sentence><sentence text="" /></document>